Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine

Solid organ transplant (SOT) recipients are a priority group for influenza vaccination and strategies enhancing immunogenicity are needed. We determined adverse reactions, changes in biomarkers of graft function and immune responses to two doses of the AS03-adjuvanted influenza A/09/H1N1 vaccine in...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2012-01, Vol.17 (5), p.893-903
Main Authors: SIEGRIST, Claire-Anne, AMBROSIONI, Juan, POSFAY-BARBE, Klara, GRILLET, Stephane, KAISER, Laurent, DELDEN, Christian Van, BEL, Michael, COMBESCURE, Christophe, HADAYA, Karine, MARTIN, Pierre-Yves, SOCCAL, Paola M, BERNEY, Thierry, NOBLE, Stephane, MEIER, Sara
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic
Adult
Age
Aged
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antibodies
Antibodies, Viral - blood
Antibodies, Viral - immunology
Antiviral agents
Bioindicators
Biological and medical sciences
biomarkers
Blood levels
calcineurin inhibitors
Cohort Studies
Female
Heart
Humans
Immune response
Immunity, Humoral - drug effects
Immunogenicity
Immunosuppressive Agents - pharmacology
Influenza
Influenza A
Influenza A Virus, H1N1 Subtype - immunology
Influenza Vaccines - adverse effects
Influenza Vaccines - immunology
Influenza, Human - prevention & control
Kidney
Liver
Lung
Male
Medical sciences
Middle Aged
Multivariate analysis
Mycophenolic acid
Organ Transplantation
Organs
Pancreas
pandemics
Pharmacology. Drug treatments
Risk groups
Side effects
Squalene - immunology
Vaccination
Vaccines
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Solid organ transplant (SOT) recipients are a priority group for influenza vaccination and strategies enhancing immunogenicity are needed. We determined adverse reactions, changes in biomarkers of graft function and immune responses to two doses of the AS03-adjuvanted influenza A/09/H1N1 vaccine in 216 SOT recipients and in 138 controls after one dose. Antibody responses were measured by haemagglutination inhibition and confirmed by microneutralization. We calculated geometric mean titres (GMT) and seroprotection rates (GMT≥40). Adverse reactions were fewer than in controls and graft function remained unaffected. Seroprotection was achieved by only 70.3% of SOT recipients, with significant differences between groups (lung 43.6%, heart 72.0%, kidney 83.3%, liver 83.3% and pancreas 85%), compared to 87% of controls (P
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP2103